High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality

Nicolas Danchin (1, 2, 3) , Tabassome Simon (4, 1)

1 FACT - Alliance française pour les essais cliniques cardio-vasculaires - French Alliance for Cardiovascular Trials
2 HEGP - Hôpital Européen Georges Pompidou [APHP]
3 SU - Sorbonne Université
4 PASS-CRB-APHP-SU - Centre de Ressources Biologiques APHP-SU

Full secondary prevention medication regimen is often under-prescribed after acute myocardial infarction.

Keywords: prevention; score; Acute myocardial infarction; mortality; prevention

Domains: Life Sciences [q-bio]

Nicolas Danchin, Tabassome Simon. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6 (4), pp.328 - 330. ⟨10.1093/ehjcvp/pvz049⟩. ⟨hal-03028620⟩